WO2018113272A1 - 一种含缩宫素类似物的药物组合物及其制备方法和用途 - Google Patents

一种含缩宫素类似物的药物组合物及其制备方法和用途 Download PDF

Info

Publication number
WO2018113272A1
WO2018113272A1 PCT/CN2017/092717 CN2017092717W WO2018113272A1 WO 2018113272 A1 WO2018113272 A1 WO 2018113272A1 CN 2017092717 W CN2017092717 W CN 2017092717W WO 2018113272 A1 WO2018113272 A1 WO 2018113272A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxytocin
pharmaceutical composition
mol
calcium
metal ion
Prior art date
Application number
PCT/CN2017/092717
Other languages
English (en)
French (fr)
Inventor
郑春莲
陶安进
卢国勇
袁建成
戴荣欢
Original Assignee
深圳翰宇药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳翰宇药业股份有限公司 filed Critical 深圳翰宇药业股份有限公司
Publication of WO2018113272A1 publication Critical patent/WO2018113272A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics

Definitions

  • the invention relates to the field of medicine, in particular to a pharmaceutical composition containing an oxytocin analog.
  • Oxytocin also known as oxytocin, is a uterine contraction drug that can be extracted or chemically synthesized from the posterior lobe of the pituitary gland. Chemical synthetic products contain no vasopressin, no boosting effect, and selective excitability to uterine smooth muscle. Function, strengthen its contraction, the uterus is most sensitive to oxytocin (increased estrogen secretion), immature uterus is not reactive to this product, the uterus is less reactive to oxytocin in early or middle pregnancy, and gradually increases in late pregnancy , the highest before the birth.
  • the small dose can strengthen the rhythmic contraction of the smooth muscle of the uterus, which makes the contractile force stronger, the contraction frequency is faster, the contraction property is similar to that of natural childbirth, and the polarity and symmetry are maintained, so it is clinically used for oxytocin and induction of labor.
  • oxytocin preparations When oxytocin preparations are used, the individual differences are large, and the sensitivities of individual uterus to oxytocin are different, which may lead to partial maternal uterine contraction and easily lead to postpartum hemorrhage. If it is not treated correctly and promptly, it will increase the chance of dystocia and midwifery, increase the chance of surgery and infection, easily lead to prolonged labor, consume maternal strength, cause postpartum hemorrhage, increase fetal birth injury, prone to fetal distress, affect neonatal prognosis .
  • the present invention provides a stable pharmaceutical composition containing an oxytocin analog as an active ingredient and a process for the preparation thereof.
  • the composition can be placed at 30 ° C for a long time, and has the advantages of more stable quality and exact curative effect.
  • One of the technical problems to be solved by the present invention is to provide a similar oxytocin-containing product for the problem of producing deamidated impurities, hydrolyzed impurities, and unknown impurities in a long-term storage of oxytocin analogs at 30 ° C.
  • Pharmaceutical composition and preparation method are provided.
  • the second technical problem to be solved by the present invention is to provide a composition for providing a pharmaceutical composition of the above oxytocin analog, in view of the technical problem that the pharmaceutical composition of the oxytocin analog is insensitive to uterine use in use. Preparation.
  • the pharmaceutical composition of the present invention unexpectedly obtains a technical effect of eliminating the difference in uterine sensitivity and preserving it at a temperature of 30 ° C for a long period of time, thereby reducing deamidation impurities, hydrolyzed impurities, and unknown impurities during long-term storage.
  • the present invention unexpectedly finds that a sample prepared by using a divalent metal ion salt can solve the problem of producing deamidated impurities, hydrolyzed impurities, unknown impurities, and eliminating uterine insensitivity in the long-term storage of oxytocin analogs at 30 ° C. problem.
  • One aspect of the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising an oxytocin analog comprising an oxytocin analog, an excipient, and a divalent metal ion salt.
  • the oxytocin analog is selected from one or a combination of two or more of oxytocin, carbetocin, naloxin, and kagotocin.
  • the divalent metal ion salt is selected from the group consisting of calcium ion salts or zinc ion salts, preferably calcium chloride, calcium acetate, calcium citrate, calcium tartrate, zinc chloride, zinc gluconate, calcium gluconate.
  • the excipient is selected from one or a combination of two or more of mannitol, lactose, glucose, sucrose, sodium chloride, sorbitol.
  • the content of each component is: from 5000 IU to 20000 IU oxytocin, correspondingly comprising 0.1 mol to 3 mol of a divalent metal ion salt and 20 g to 100 g of an excipient;
  • carbetocin per 0.1 g of carbetocin, correspondingly comprises 0.1 mol to 3 mol of a divalent metal ion salt and 20 g to 100 g of an excipient.
  • the formulation is selected from the group consisting of injectable powders.
  • Another aspect of the present invention provides a method of preparing the pharmaceutical composition of the present invention, comprising the steps of:
  • Step 3) The prepared solution is sterilized and lyophilized
  • the pH of the divalent metal ion salt solution in step 1) is adjusted to 3.5-6.9.
  • lyophilization is to reduce the temperature to below -40 ° C, and the temperature is increased after the vacuum is turned on.
  • the concentration ratio of each component in the solution obtained in the step 3) is 5,000 IU/L to 20,000 IU/L oxytocin, correspondingly containing 0.1 mol/L to 3 mol/L of the divalent metal ion salt and 20 g/L-100 g. /L excipient; or every 0.1 g/L carbetocin, corresponding to 0.1 mol/L to 3 mol/L of divalent metal ion salt and 20 g/L to 100 g/L of excipient.
  • the lyophilization procedure is to lower the temperature to below -40 ° C, and keep the temperature for 1.5-3 hours; turn on the vacuum, and raise the temperature to -35 ° C to -25 ° C for 2-10 hours, -20 ° C ⁇ -10 ° C for 2-10 hours, -5 ° C ⁇ 5 ° C for 2-10 hours, 10 ° C ⁇ 35 ° C for 5-10 hours.
  • the oxytocin powder is formulated in the following ratios:
  • a divalent metal ion salt solution (optionally, adjusting the pH to 3.5-6.9), adding an excipient, oxytocin to dissolve and mix; continuing to add a divalent metal ion salt solution to the total volume; preparing the solution Filtered through a 0.22 ⁇ m filter, dispensed, and lyophilized.
  • the carbetocin powder is formulated in the following proportions:
  • a divalent metal ion salt solution (optionally, adjusting the pH to 3.5-6.9), adding an excipient, oxytocin to dissolve and mix; continuing to add a divalent metal ion salt solution to the total volume; preparing the solution Filtered through a 0.22 ⁇ m filter, dispensed, and lyophilized.
  • the oxytocin powder is formulated in the following ratios:
  • the oxytocin powder is formulated in the following ratios:
  • a 0.5 mol/L calcium chloride solution was prepared, and mannitol and oxytocin were added to dissolve and mix.
  • the 0.5 mol/L calcium chloride solution was continuously added to the total volume; the prepared solution was sterilized by a 0.22 ⁇ m filter and packed at 0.5 ml/pack. Freeze dried.
  • the oxytocin powder is formulated in the following ratios:
  • the oxytocin powder is formulated in the following ratios:
  • the oxytocin powder is formulated in the following ratios:
  • the carbetocin powder is formulated in the following proportions:
  • a further aspect of the invention provides the use of a pharmaceutical composition of the invention in the manufacture of a medicament for uterine contraction or uterine hemostasis.
  • a further aspect of the invention provides the use of a pharmaceutical composition of the invention in the manufacture of a medicament for increasing uterine sensitivity or eliminating uterine sensitivity differences.
  • the pH adjusting agent used for the pH of the divalent metal ion salt solution to 3.5-6.9 is selected from the group consisting of gluconic acid, gluconolactone, malic acid, citric acid, acetic acid, and tartaric acid;
  • the divalent metal ion solution is selected from the group consisting of calcium chloride, calcium acetate, calcium citrate, calcium tartrate, zinc chloride, zinc gluconate, calcium gluconate, calcium sulfate, zinc sulfate, zinc acetate, and zinc citrate. Or a combination of two or more;
  • the pharmaceutical composition of the present invention can eliminate the difference in uterine sensitivity and has a stable technical effect at a temperature of 30 ° C for a long period of time.
  • the pharmaceutical composition of the invention has high stability and can be stored for a long period of time, and the deamidation impurities, hydrolysis impurities and unknown impurities can be controlled at a low level.
  • Example 1 The oxytocin powder was prepared using the prior art.
  • the sheet temperature was lowered to below -40 ° C in 1 hour and held for 3 hours.
  • the vacuum was turned on, the temperature was raised, the temperature was raised at -25 ° C for 2 hours, the temperature was kept at -20-10 ° C for 2 hours, the temperature was kept at -5 ° C for 2 hours, the temperature was kept at 10 ° C for 5 hours, and the temperature was kept at 35 ° C for 5 hours.
  • Example 2 The oxytocin powder was prepared using the prior art.
  • the sheet temperature was lowered to below -40 ° C in 1 hour and held for 1.5-3 hours.
  • the vacuum is turned on, the temperature is raised, the temperature is maintained at -35 to -25 ° C for 2 hours, the temperature is maintained at -20 to -10 ° C for 2 hours, the temperature is maintained at -5 to 5 ° C for 2 hours, and the temperature is maintained at 10 to 35 ° C for 5 hours.
  • Example 3 used a oxytocin powder prepared by the prior art.
  • the sheet temperature was lowered to below -40 ° C in 1 hour and held for 1.5-3 hours.
  • the vacuum is turned on, the temperature is raised, the temperature is maintained at -35 to -25 ° C for 2 hours, the temperature is maintained at -20 to -10 ° C for 2 hours, the temperature is maintained at -5 to 5 ° C for 2 hours, and the temperature is maintained at 10 to 35 ° C for 5 hours.
  • Example 4 The oxytocin powder of the present invention
  • a 0.1 mol/L calcium gluconate solution was prepared, and the pH was adjusted to pH 3.5 with gluconic acid, and mannitol and oxytocin were added to dissolve and mix.
  • the calcium gluconate solution was continuously added to the total volume; the prepared solution was sterilized by a 0.22 ⁇ m filter and packed at 1.0 ml/pack. Freeze dried.
  • the sheet temperature was lowered to below -40 ° C in 1 hour and held for 1.5-3 hours.
  • the vacuum is turned on, the temperature is raised, the temperature is maintained at -35 to -25 ° C for 2 hours, the temperature is maintained at -20 to -10 ° C for 2 hours, the temperature is maintained at -5 to 5 ° C for 2 hours, and the temperature is maintained at 10 to 35 ° C for 5 hours.
  • Example 5 The oxytocin powder of the present invention
  • a 0.5 mol/L calcium chloride solution was prepared, and mannitol and oxytocin were added to dissolve and mix.
  • the 0.5 mol/L calcium chloride solution was continuously added to the total volume; the prepared solution was sterilized by a 0.22 ⁇ m filter and packed at 0.5 ml/pack. Freeze dried.
  • the sheet temperature was lowered to below -40 ° C in 1 hour and held for 1.5-3 hours. Turn on the vacuum, start to heat up, hold at -35 ⁇ -25 °C for 2 hours, -20 ⁇ -10 °C for 2 hours, -5 to 5 °C for 2 hours, 10 ⁇ Incubate at 35 ° C for 5 hours.
  • Example 6 The oxytocin powder of the present invention
  • the sheet temperature was lowered to below -40 ° C in 1 hour and held for 1.5-3 hours.
  • the vacuum was turned on and the temperature was raised.
  • the temperature was maintained at -35 to -25 ° C for 5 hours, the temperature was maintained at -20 to -10 ° C for 5 hours, the temperature was maintained at -5 to 5 ° C for 5 hours, and the temperature was maintained at 10 to 35 ° C for 8 hours.
  • Example 7 oxytocin powder of the present invention
  • the sheet temperature was lowered to below -40 ° C in 1 hour and held for 1.5-3 hours.
  • the vacuum is turned on, the temperature is raised, the temperature is maintained at -35 to -25 ° C for 5 hours, the temperature is maintained at -20 to -10 ° C for 10 hours, the temperature is maintained at -5 to 5 ° C for 10 hours, and the temperature is maintained at 10 to 35 ° C for 10 hours.
  • a 0.1 mol/L calcium citrate solution was prepared, and the pH was adjusted to pH 6.9 with acetic acid, and mannitol and oxytocin were added to dissolve and mix.
  • the calcium citrate solution was continuously added to the total volume; the prepared solution was sterilized by a 0.22 ⁇ m filter and packed at 1.0 ml/pack. Freeze dried.
  • the sheet temperature was lowered to below -40 ° C in 1 hour and held for 1.5-3 hours.
  • the vacuum is turned on, the temperature is raised, the temperature is maintained at -35 to -25 ° C for 2 hours, the temperature is maintained at -20 to -10 ° C for 2 hours, the temperature is maintained at -5 to -5 ° C for 2 hours, and the temperature is maintained at 10 to 35 ° C for 5 hours.
  • Example 9 The carbetocin powder of the present invention
  • the sheet temperature was lowered to below -40 ° C in 1 hour and held for 1.5-3 hours.
  • the vacuum is turned on, the temperature is raised, the temperature is maintained at -35 to -25 ° C for 2 hours, the temperature is maintained at -20 to -10 ° C for 2 hours, the temperature is maintained at -5 to 5 ° C for 2 hours, and the temperature is maintained at 10 to 35 ° C for 5 hours.
  • the oxytocin powder prepared in the prior art of Example 1-3 was larger at 0 month, and after being placed at 30 ° C for 36 months, the hydrolysis impurity was 1.6-2.7. %, deamidated impurities are 1.2-1.8.%, unknown impurities are 1.5-2.0%, total impurities are 8.3-8.9%, deamidation impurities, hydrolyzed impurities, unknown impurities and total impurities are greatly increased; content is 84-85% , greatly degraded.
  • the samples of Examples 4-9 of the present invention are small in the month of 0, and after being placed at 30 ° C for 36 months, the deamidated impurities, the hydrolyzed impurities, and the unknown impurities are not more than 0.2%, and the deamidated impurities, the hydrolyzed impurities and the unknown impurities are not present. Significant increase; total miscellaneous no more than 0.55%, the content is still 98%.
  • the pharmaceutical combination of the oxytocin analog of the present invention can be placed at 30 ° C for a long period of 36 months.
  • the oxytocin analog composition provided by the invention can be rapidly dissolved in water for injection, 0.9% sodium chloride injection or 5% glucose injection, and the solution is colorless and clear without impurity precipitation after dissolution. Moreover, the oxytocin powder and the carbetocin powder provided by the present invention all exhibit stable properties under the conditions of long-term stability data at 30 °C.
  • Example 11 Animal safety test of oxytocin analog pharmaceutical composition prepared in Examples 4-9 of the present invention
  • the irritative response of the ear vein was observed regularly every day.
  • the rabbits were sacrificed.
  • the bilateral ear veins and surrounding tissues were taken and fixed with formaldehyde.
  • the proximal myocardium was 11, 21, 31 mm from the injection site for routine tissue section.
  • the pathological changes were observed under light microscope. The observation indicators and judgment criteria are shown in Table 3.
  • the rabbit rim vein was injected with the oxytocin analog pharmaceutical composition prepared in each of Examples 4-9 of the present invention, and the irritant was compared with the 5% glucose injection. No significant difference.
  • Visual observation showed no inflammatory reaction such as vascular congestion and surrounding tissue edema.
  • Tissue biopsy showed no abnormal vascular structure, endothelial damage, thrombosis and other pathological changes.
  • the cumulative scores of the blood vessels and the surrounding tissues observed by the naked eye and the light microscope were all less than 0.5, indicating that the oxytocin powder and the carbetocin powder prepared in Examples 4-9 of the present invention were not irritating to blood vessels.
  • Level 0 There was no significant reaction at the site of administration.
  • Level 1 The site of administration was slightly hyperemic and the diameter was less than 0.15 cm.
  • level 2 The site of administration was moderately hyperemic, with a diameter of 0.15-1.0 cm.
  • Level 3 The site of administration was severely hyperemic, red and swollen, and the muscles were degenerated.
  • level 4 Muscle brown degeneration and necrosis.
  • Level 5 Muscles are severely degenerated and large areas of necrosis occur.
  • the oxytocin powder and the carbetocin powder prepared in Example 4-9 of the present invention were injected into the left quadriceps of the rabbit, and the muscle at the injection site was visually observed. Congestive, water There was no significant stimuli such as tissue degeneration or necrosis in the pathological examination, and there was no significant difference compared with the saline side.
  • guinea pigs Forty-eight healthy guinea pigs were randomly divided into the experimental group, the negative control group and the positive control group, and the negative control group was given the same volume of the vehicle; the positive control group was given the known sensitizing substance for bovine serum albumin; 1.0 ml of the oxytocin pharmaceutical analogue composition prepared in Examples 4-9 (each of Example 6) of the present invention was intraperitoneally injected, once every other day, for a total of 3 injections. Then, 2 groups were randomly divided into groups, 14 days or 21 days after the first administration, and the injection was intravenously injected to observe whether the guinea pig had allergic symptoms such as excitement and difficulty in breathing.
  • a 2% rabbit red blood cell suspension was prepared. Seven tubes were taken from each group, and various liquids were added according to Table 5. The tubes were gently shaken and incubated in a constant temperature water bath at 37 ° C to observe the results for 0.5, 1, 2, 3, and 6 hours. The criteria for judging the in vitro agglutination and hemolysis of erythrocytes are shown in Table 6.
  • the oxytocin powder and the carbetocin powder prepared in Examples 4-9 were each dissolved in water for injection.
  • the distilled water control tube was completely hemolyzed at 0.5 hour.
  • the physiological saline and the oxytocin powder and the carbetocin powder of Examples 4-9 of the present invention were not hemolyzed within 3 hours.
  • the red blood cells deposited by the saline and oxytocin needles and the carbetocin powder can be completely dispersed, indicating that the pharmaceutical composition of the oxytocin analog of the present invention has no red blood cell agglutination reaction.
  • mice 35 healthy mice were randomly divided into a test group and a control group, and the mice were placed in a holder.
  • the test group was injected with the oxytocin analog pharmaceutical composition prepared in Examples 4-9 of the present invention from the tail vein for the test solution (5 in each example), and the control group was injected with the blank control solution at an injection rate of 0.1 ml/ s, the injection dose is 50 ml/kg.
  • the mice were observed to react immediately, and at 4, 24, 48, and 72 hours, the general state, toxicity, and number of dead animals of the test group and the control group were observed and recorded.
  • the injection of the pharmaceutical composition of the oxytocin analog prepared in Examples 4-9 of the present invention has good histocompatibility. It is indicated that the pharmaceutical composition of the oxytocin analog prepared by the invention has good safety and can be used for clinical injection.
  • the nutrient solution in the bath is suitable for immersing the uterus.
  • the temperature of the water bath was 37 ⁇ 0.5 ° C, and it was allowed to stand for 15 min. After the uterus was adapted, the experiment was started. Open the BL-420F biological function experiment system and start the experiment. Examples 1-9 were separately dissolved with 1 ml of water for injection and administration was started. Calculate the intensity, frequency, and uterine contractile viability of uterine contractions.
  • Examples 4-9 of the present invention had significant excitatory effects on isolated uterine smooth muscle of rats and rabbits, and the amplitude of contraction was increased, the frequency was increased, the tension was increased, and the dose-effect relationship was obtained.
  • Example 4 of the present invention -9 can produce the same excitatory effects on different uterus, and there is no difference in effect on individuals.
  • Examples 1-3 have an excitatory effect on rat uterine smooth muscle, the excitatory effects on rabbit uterine smooth muscle are weak, and there are individual differences.

Abstract

本发明涉及一种含缩宫素类似物的药物组合物及其制备方法和用途。所述药物组合物包含缩宫素类似物、赋形剂和2价金属离子盐。2价金属离子盐选自氯化钙、醋酸钙、柠檬酸钙、酒石酸钙、氯化锌、葡萄糖酸锌、葡萄糖酸钙、硫酸钙、硫酸锌、醋酸锌、柠檬酸锌中的一种或两种以上组合的溶液。本发明的药物组合物能消除子宫敏感性差异且在能30℃长期保存的稳定。

Description

一种含缩宫素类似物的药物组合物及其制备方法和用途 技术领域
本发明涉及药物领域，具体涉及一种含缩宫素类似物的药物组合物。
背景技术
缩宫素，又称催产素，是一种子宫收缩药，可从动物脑垂体后叶中提取或化学合成，化学合成品不含加压素，无升压作用，对子宫平滑肌有选择性兴奋作用，加强其收缩，临产子宫对缩宫素最敏感(雌激素分泌增加)，未成熟子宫对本品无反应性，妊娠早期或中期子宫对催产素的反应性较低，妊娠后期则逐渐增高，至临产前达最高。小剂量可加强子宫底部平滑肌的节律收缩，使其收缩力加强，收缩频率加快，收缩性质与自然分娩类似，并保持极性和对称性，故临床用于催产、引产。
缩宫素制剂使用时因个体差异大，个体子宫对缩宫素的敏感性存在差异，会导致部分产妇子宫收缩乏力，容易导致产后出血。倘若不正确、及时处理，易增加难产及助产机会，增加手术产及感染机会，容易导致产程延长，消耗产妇体力，引起产后大出血，使胎儿产伤增多，容易发生胎儿窘迫，影响新生儿预后。
中国幅员辽阔，夏季除了地势高的青藏高原和天山等以外，大部地区在20℃以上，南方许多地方在28℃以上。因此需开发一种能消除子宫敏感性差异且在30℃长期保存的稳定的缩宫素的药用组合物。
中国药典2015版规定市售的注射用缩宫素和缩宫素注射液的存储条件均为在凉暗处保存，凉暗处保存指遮光在20℃以下贮藏。卡贝缩宫素注射液为2-8℃贮藏。
中国幅员辽阔，夏季除了地势高的青藏高原和天山等以外，大部地区在20℃以上，南方许多地方在28℃以上。因此需开发一种能消除子宫敏感性差异且在30℃长期保存的稳定的缩宫素类似物的药用组合物。
发明内容
有鉴于此，本发明提供了一种稳定的含缩宫素类似物为活性成分的药用组合物及制备方法。该组合物可以在30℃下长期放置，具有质量更稳定，疗效确切的优势。
本发明所要解决的技术问题之一在于针对缩宫素类似物药用组合物在30℃长期存放中产生脱酰胺杂质、水解杂质、未知杂质的技术问题而提供一种提供上述含缩宫素类似物的药用组合物及制备方法。
本发明所要解决的技术问题之二在于针对缩宫素类似物的药用组合物在使用中子宫不敏感的技术问题而提供一种提供上述缩宫素类似物的药用组合物的组合物及制备方法。
本发明的药用组合物意外的获得一种能消除子宫敏感性差异且在能30℃长期保存，降低长期存放中产生脱酰胺杂质、水解杂质、未知杂质的技术效果。
本发明意外的发现采用2价金属离子盐制备的样品能解决缩宫素药类似物药用组合物在30℃长期存放中产生脱酰胺杂质、水解杂质、未知杂质的问题和消除子宫不敏感的问题。
本发明一个方面提供了一种含缩宫素类似物的药物组合物，其包含缩宫素类似物、赋形剂以及2价金属离子盐。
在本发明的实施方案中，缩宫素类似物选自缩宫素、卡贝缩宫素、那卡缩宫素、卡古缩宫素中的一种或两种以上组合。
在本发明的实施方案中，2价金属离子盐选自钙离子盐或锌离子盐，优选为氯化钙、醋酸钙、柠檬酸钙、酒石酸钙、氯化锌、葡萄糖酸锌、葡萄糖酸钙、硫酸钙、硫酸锌、醋酸锌、柠檬酸锌中的一种或两种以上组合的溶液。
在本发明的实施方案中，赋形剂选自甘露醇、乳糖、葡萄糖、蔗糖、氯化钠、山梨醇中的一种或两种以上组合。
在本发明的实施方案中，各组分的含量为：每5000IU-20000IU缩宫素，对应包含0.1mol-3mol的2价金属离子盐以及20g-100g赋形剂；
或者每0.1g卡贝缩宫素，对应包含0.1mol-3mol的2价金属离子盐以及20g-100g赋形剂。
在本发明的实施方案中，其制剂选自注射用粉针剂。
本发明另一个方面提供了本发明所述药物组合物的制备方法，其包括如下步骤:
1)配制0.1mol/L-3mol/L 2价金属离子盐溶液；
2)加入赋形剂、缩宫素类似物并混合均匀；
3)继续加入2价金属离子盐溶液至总体积；
4)步骤3)配制好的溶液灭菌后冻干；
可选地，调节步骤1)中的2价金属离子盐溶液pH值至3.5-6.9。
优选地，冻干为降温至-40℃以下，并开启真空后进行程序性升温。
优选地，步骤3)所得溶液中的各组分浓度比例为每5000IU/L-20000IU/L缩宫素，对应包含0.1mol/L-3mol/L的2价金属离子盐以及20g/L-100g/L赋形剂；或者每0.1g/L卡贝缩宫素，对应包含0.1mol/L-3mol/L的2价金属离子盐以及20g/L-100g/L赋形剂。
在本发明的具体技术方案中，冻干程序为将温度降至-40℃以下，保温1.5-3小时；开启真空，升温至-35℃～-25℃保温2-10小时，-20℃～-10℃保温2-10小时，-5℃～5℃保温2-10小时，10℃～35℃保温5-10小时。
在本发明的一个具体实施方案中，缩宫素粉针按照以下比例配制：
Figure PCTCN2017092717-appb-000001
配制2价金属离子盐溶液(可选地，调节pH值至3.5-6.9)，加入赋形剂、缩宫素溶解混匀；继续加入2价金属离子盐溶液至总体积；将配制好的溶液经0.22μm过滤器除菌过滤，分装，冻干。
在本发明的一个具体实施方案中，卡贝缩宫素粉针按照以下比例配制：
Figure PCTCN2017092717-appb-000002
配制2价金属离子盐溶液(可选地，调节pH值至3.5-6.9)，加入赋形剂、缩宫素溶解混匀；继续加入2价金属离子盐溶液至总体积；将配制好的溶液经0.22μm过滤器除菌过滤，分装，冻干。
在本发明的一个具体实施方案中，缩宫素粉针按照以下比例配制：
Figure PCTCN2017092717-appb-000003
Figure PCTCN2017092717-appb-000004
配制0.1mol/L葡萄糖酸钙溶液，用葡萄糖酸调节pH至pH3.5，加入甘露醇、缩宫素溶解混匀；继续加入葡萄糖酸钙溶液至总体积；将配制好的溶液经0.22μm过滤器除菌过滤，以1.0ml/支分装；冻干。
在本发明的一个具体实施方案中，缩宫素粉针按照以下比例配制：
Figure PCTCN2017092717-appb-000005
配制0.5mol/L氯化钙溶液，加入甘露醇、缩宫素溶解混匀。继续加入0.5mol/L氯化钙溶液至总体积；将配制好的溶液经0.22μm过滤器除菌过滤，以0.5ml/支分装。冻干。
在本发明的一个具体实施方案中，缩宫素粉针按照以下比例配制：
Figure PCTCN2017092717-appb-000006
配制1.5mol/L硫酸锌溶液，用苹果酸调节pH至5.0，加入乳糖、缩宫素溶解混匀；继续加入硫酸锌溶液至总体积；将配制好的溶液经0.22μm过滤器除菌过滤，以5.0ml/支分装；冻干。
在本发明的一个具体实施方案中，缩宫素粉针按照以下比例配制：
Figure PCTCN2017092717-appb-000007
配制2mol/L硫酸钙溶液，用酒石酸调节pH至5.5，加入蔗糖、缩宫素溶解 混匀。继续加入硫酸钙溶液至总体积；将配制好的溶液经0.22μm过滤器除菌过滤，以10.0ml/支分装。冻干。
在本发明的一个具体实施方案中，缩宫素粉针按照以下比例配制：
Figure PCTCN2017092717-appb-000008
配制0.1mol/L柠檬酸钙溶液，用醋酸调节pH至pH6.9，加入甘露醇、缩宫素溶解混匀；继续加入柠檬酸钙溶液至总体积；将配制好的溶液经0.22μm过滤器除菌过滤，以1.0ml/支分装；冻干。
在本发明的一个具体实施方案中，卡贝缩宫素粉针按照以下比例配制：
Figure PCTCN2017092717-appb-000009
配制0.1mol/L柠檬酸钙溶液，用醋酸调节pH至pH4.5，加入甘露醇、卡贝缩宫素溶解混匀；继续加入柠檬酸钙溶液至总体积；将配制好的溶液经0.22μm过滤器除菌过滤，以1.0ml/支分装；冻干。
本发明再一个方面提供了本发明的药物组合物在制备用于子宫收缩或子宫止血的药物中的用途。
本发明再一个方面提供了本发明的药物组合物在制备用于提高子宫敏感性或消除子宫敏感性差异的药物中的用途。
在本发明的技术方案中，2价金属离子盐溶液pH值至3.5-6.9所用的pH调节剂选自葡萄糖酸、葡萄酸内酯、苹果酸、柠檬酸、醋酸、酒石酸；
其2价金属离子溶液选自氯化钙、醋酸钙、柠檬酸钙、酒石酸钙、氯化锌、葡萄糖酸锌、葡萄糖酸钙、硫酸钙、硫酸锌、醋酸锌中、柠檬酸锌的一种或两种以上组合的溶液；
有益效果
本发明药用组合物能消除子宫敏感性差异且在能30℃长期保存的稳定的技术效果。
本发明药用组合物稳定性高，能够长期储存，脱酰胺杂质、水解杂质、未知杂质能够控制在低水平。
具体实施方式
下面用实施例来进一步说明本发明，但本发明并不受其限制。
实施例1采用现有技术制备缩宫素粉针。
缩宫素                          10000IU
甘露醇                          50.0g
加注射用水至总体积              1000ml
按处方量称取原辅料，用注射用水将甘露醇，缩宫素溶解混匀，继续加入适量注射用水至总体积；将配制好的溶液经0.22μm过滤器除菌过滤，以1.0ml/支分装。冻干。
用1小时内将板层温度降至-40℃以下，保温3小时。开启真空，开始升温，-25℃保温2小时，-20-10℃保温2小时，-5℃保温2小时,10℃保温5小时，35℃保温5小时。
实施例2采用现有技术制备缩宫素粉针。
Figure PCTCN2017092717-appb-000010
按处方量称取原辅料，用注射用水分别溶解缩宫素、甘露醇，并混匀。用柠檬酸调节pH至3.5，继续添加注射用至总体积，0.2um过滤，以1.0ml/支分装。冻干。
用1小时内将板层温度降至-40℃以下，保温1.5-3小时。开启真空，开始升温，-35～-25℃保温2小时，-20～-10℃保温2小时，-5～5℃保温2小时,10～35℃保温5小时。
实施例3采用现有技术制备的缩宫素粉针。
Figure PCTCN2017092717-appb-000011
Figure PCTCN2017092717-appb-000012
按处方量称取原辅料，用注射用水分别溶解缩宫素、甘露醇、半胱氨酸盐酸盐，并混匀。继续添加注射用至总体积，0.2um过滤，以1.0ml/支分装。冻干。
用1小时内将板层温度降至-40℃以下，保温1.5-3小时。开启真空，开始升温，-35～-25℃保温2小时，-20～-10℃保温2小时，-5～5℃保温2小时，10～35℃保温5小时。
实施例4本发明的缩宫素粉针
Figure PCTCN2017092717-appb-000013
配制0.1mol/L葡萄糖酸钙溶液，用葡萄糖酸调节pH至pH3.5，加入甘露醇、缩宫素溶解混匀。继续加入葡萄糖酸钙溶液至总体积；将配制好的溶液经0.22μm过滤器除菌过滤，以1.0ml/支分装。冻干。
用1小时内将板层温度降至-40℃以下，保温1.5-3小时。开启真空，开始升温，-35～-25℃保温2小时，-20～-10℃保温2小时，-5～5℃保温2小时,10～35℃保温5小时。
实施例5本发明的缩宫素粉针
Figure PCTCN2017092717-appb-000014
配制0.5mol/L氯化钙溶液，加入甘露醇、缩宫素溶解混匀。继续加入0.5mol/L氯化钙溶液至总体积；将配制好的溶液经0.22μm过滤器除菌过滤，以0.5ml/支分装。冻干。
用1小时内将板层温度降至-40℃以下，保温1.5-3小时。开启真空，开始升温，-35～-25℃保温2小时，-20～-10℃保温2小时，-5～5℃保温2小时,10～ 35℃保温5小时。
实施例6本发明的缩宫素粉针
Figure PCTCN2017092717-appb-000015
配制1.5mol/L硫酸锌溶液，用苹果酸调节pH至5.0，加入乳糖、缩宫素溶解混匀。继续加入硫酸锌溶液至总体积；将配制好的溶液经0.22μm过滤器除菌过滤，以5.0ml/支分装。冻干。
用1小时内将板层温度降至-40℃以下，保温1.5-3小时。开启真空，开始升温，-35～-25℃保温5小时，-20～-10℃保温5小时，-5～5℃保温5小时,10～35℃保温8小时。
实施例7本发明的缩宫素粉针
Figure PCTCN2017092717-appb-000016
配制2mol/L硫酸钙溶液，用酒石酸调节pH至5.5，加入蔗糖、缩宫素溶解混匀。继续加入硫酸钙溶液至总体积；将配制好的溶液经0.22μm过滤器除菌过滤，以10.0ml/支分装。冻干。
用1小时内将板层温度降至-40℃以下，保温1.5-3小时。开启真空，开始升温，-35～-25℃保温5小时，-20～-10℃保温10小时，-5～5℃保温10小时,10～35℃保温10小时。
实施例8本发明的缩宫素粉针
Figure PCTCN2017092717-appb-000017
Figure PCTCN2017092717-appb-000018
配制0.1mol/L柠檬酸钙溶液，用醋酸调节pH至pH6.9，加入甘露醇、缩宫素溶解混匀。继续加入柠檬酸钙溶液至总体积；将配制好的溶液经0.22μm过滤器除菌过滤，以1.0ml/支分装。冻干。
用1小时内将板层温度降至-40℃以下，保温1.5-3小时。开启真空，开始升温，-35～-25℃保温2小时，-20～-10℃保温2小时，-5～-5℃保温2小时,10～35℃保温5小时。
实施例9本发明的卡贝缩宫素粉针
Figure PCTCN2017092717-appb-000019
配制0.1mol/L柠檬酸钙溶液，用醋酸调节pH至pH4.5，加入甘露醇、卡贝缩宫素溶解混匀；继续加入柠檬酸钙溶液至总体积；将配制好的溶液经0.22μm过滤器除菌过滤，以1.0ml/支分装；冻干。
用1小时内将板层温度降至-40℃以下，保温1.5-3小时。开启真空，开始升温，-35～-25℃保温2小时，-20～-10℃保温2小时，-5～5℃保温2小时,10～35℃保温5小时。
实施例10稳定性试验
将实施例1-9样品以及市售缩宫素注射液
Figure PCTCN2017092717-appb-000020
在30℃±2℃，65％RH±5％RH的条件下长期放置。结果参见表1。
表格1 30℃长期存放稳定性数据
Figure PCTCN2017092717-appb-000021
Figure PCTCN2017092717-appb-000022
Figure PCTCN2017092717-appb-000023
研究发现在制备缩宫素粉针时，实施例1-3采用现有技术制备的缩宫素粉针在0月时有关物质较大，且30℃放置36月后，水解杂质为1.6-2.7％，脱酰胺杂质为1.2-1.8.％，未知杂质为1.5-2.0％，总杂为8.3-8.9％，脱酰胺杂质、水解杂质、未知杂质和总杂大幅度增加；含量为84-85％，大幅度降解。
Figure PCTCN2017092717-appb-000024
(缩宫素注射液)在30℃放置36月，脱酰胺杂质为1.5％，未知杂质为3.6％，总杂为13.0％，脱酰胺杂质、水解杂质、未知杂质和总杂大幅度增加；含量为88.2％，大幅度降解。
本发明的实施例4-9样品0月时有关物质小，且在30℃放置36月后，脱酰胺杂质、水解杂质、未知杂质均不大于0.2％，脱酰胺杂质、水解杂质和未知杂质无显著增加；总杂不超过0.55％，含量仍有98％。
由此可见，本发明的缩宫素类似物药用组合能在30℃长期放置36月。
本发明提供的缩宫素类似物组合物在注射用水、0.9％氯化钠注射液或5％葡萄糖注射液中能迅速溶解，溶解后溶液无色澄清无杂质沉淀。且本发明提供的缩宫素粉针和卡贝缩宫素粉针在30℃长期稳定性数据的条件下皆表现出稳定的性质。
将实施例4-9样品40℃±2℃/65％RH±5％RH的条件下6个月，结果参见表2。
表格2 40℃加速6月稳定性数据
Figure PCTCN2017092717-appb-000025
Figure PCTCN2017092717-appb-000026
实施例11：本发明实施例4-9制备的缩宫素类似物药用组合物动物安全性试验
1、血管刺激性试验
选取双耳无损伤的健康家兔36只，左侧耳缘静脉分别注射本发明实施例(每个实施例6只)制备的缩宫素类似物药用组合物1ml，右耳注射等容量的5％葡萄糖注射液，每天1次，连续注射7天。
注射期间，每天定时观察耳缘静脉的刺激性反应。第8天处死家兔，取双侧耳缘静脉及周围组织，用甲醛固定，在距注射部位分别为11、21、31mm的近心端作常规组织切片，光镜下观察有无病理变化。观察指标及判断标准见表3。
表格3血管刺激性评分及判断标准
Figure PCTCN2017092717-appb-000027
Figure PCTCN2017092717-appb-000028
按照上述方法以及表3的评分及判断标准，家兔耳缘静脉注射本发明实施例4-9分别制备的缩宫素类似物药用组合物，其刺激性与5％葡萄糖注射液相比，无明显差异。肉眼观察，未见血管充血，周围组织水肿等炎症反应。组织切片检查，未见血管结构异常，内皮损伤，血栓形成及其他病理变化。其肉眼和光镜观察的血管，周围组织的累积得分均小于0.5，表明本发明实施例4-9分别制备的缩宫素粉针和卡贝缩宫素粉针对血管无刺激性。
2、肌肉刺激性试验
取健康家兔36只，每只家兔左侧股四头肌分别注射本发明实施例4-9(每个实施例6只)制备的缩宫素类似物药用组合物1ml，右侧注射同体积生理盐水。注射后观察注射部位肌肉有无充血，水肿等反应，半数动物48h后(第3天)放血处死，纵向切开皮肤，肉眼观察两侧注射部位有无充血，水肿等反应，并取其组织做病理检查。然后按表4的标准评价该药的刺激反应。余下动物继续观察14d，于第18天放血处死后重复上述操作，评价标准见表4。
表格4肌肉刺激性反应评价标准
级别 刺激反应现象
0级 给药部位无明显反应。
1级 给药部位轻度充血，直径小于0.15cm。
2级 给药部位中度充血，直径0.15-1.0cm。
3级 给药部位重度充血，红肿，肌肉有变性。
4级 出现肌肉褐色变性，坏死。
5级 肌肉严重变性，出现大面积坏死。
按照上述方法以及表3的评价标准，家兔左侧股四头肌内注射本发明实施例4-9制备的缩宫素粉针和卡贝缩宫素粉针后，肉眼观察注射部位肌肉无充血，水 肿等反应，病理组织检查亦未见组织变性或坏死等明显性刺激反应，与生理盐水侧相比无显著性差异。
3、对豚鼠的致敏试验
选取健康豚鼠48只，将豚鼠随机分为试验组、阴性对照组和阳性对照组，阴性对照组给予同体积的溶媒；阳性对照组给予牛血清白蛋白已知致敏阳性物质；试验组每只腹腔注射本发明实施例4-9(每个实施例6只)制备的缩宫素药用类似物组合物1.0ml，隔日注射1次，共注射3次。然后随机各分2组，分别在第1次给药后14天或21天，静注注射液，观察豚鼠有无兴奋不安，呼吸困难等过敏症状。
结果表明，试验组豚鼠均活动正常，未见呼吸异常等，未有过敏反应。
4、体外溶血性试验
制备2％家兔红细胞悬液。每组取试管7支，按表5加入各种液体。将各试管轻轻摇匀，置37℃恒温水浴中孵育，观察0.5、1、2、3、6小时的结果。红细胞体外凝集与溶血的判断标准见表6。实施例4-9制备的缩宫素粉针和卡贝缩宫素粉针分别用注射用水溶解。
表格5注射液体外溶血试验加样表
样品/管号 1 2 3 4 5 6 7
0.9％氯化钠注射液(ml) 2.4 2.3 2.2 2.1 2.0 2.5 0
实施例4(ml) 0.1 0.2 0.3 0.4 0.5 0 0
蒸馏水(ml) 0 0 0 0 0 0 2.5
2％红细胞悬液(ml) 2.5 2.5 2.5 2.5 2.5 2.5 2.5
样品/管号 1 2 3 4 5 6 7
0.9％氯化钠注射液(ml) 2.4 2.3 2.2 2.1 2.0 2.5 0
实施例5(ml) 0.1 0.2 0.3 0.4 0.5 0 0
蒸馏水(ml) 0 0 0 0 0 0 2.5
2％红细胞悬液(ml) 2.5 2.5 2.5 2.5 2.5 2.5 2.5
样品/管号 1 2 3 4 5 6 7
0.9％氯化钠注射液(ml) 2.4 2.3 2.2 2.1 2.0 2.5 0
实施例6(ml) 0.1 0.2 0.3 0.4 0.5 0 0
蒸馏水(ml) 0 0 0 0 0 0 2.5
2％红细胞悬液(ml) 2.5 2.5 2.5 2.5 2.5 2.5 2.5
样品/管号 1 2 3 4 5 6 7
0.9％氯化钠注射液(ml) 2.4 2.3 2.2 2.1 2.0 2.5 0
实施例7(ml) 0.1 0.2 0.3 0.4 0.5 0 0
蒸馏水(ml) 0 0 0 0 0 0 2.5
2％红细胞悬液(ml) 2.5 2.5 2.5 2.5 2.5 2.5 2.5
样品/管号 1 2 3 4 5 6 7
0.9％氯化钠注射液(ml) 2.4 2.3 2.2 2.1 2.0 2.5 0
实施例8(ml) 0.1 0.2 0.3 0.4 0.5 0 0
蒸馏水(ml) 0 0 0 0 0 0 2.5
2％红细胞悬液(ml) 2.5 2.5 2.5 2.5 2.5 2.5 2.5
样品/管号 1 2 3 4 5 6 7
0.9％氯化钠注射液(ml) 2.4 2.3 2.2 2.1 2.0 2.5 0
实施例9(ml) 0.1 0.2 0.3 0.4 0.5 0 0
蒸馏水(ml) 0 0 0 0 0 0 2.5
2％红细胞悬液(ml) 2.5 2.5 2.5 2.5 2.5 2.5 2.5
表格6红细胞体外溶血与凝集试验判断标准
Figure PCTCN2017092717-appb-000029
按照上述方法以及表6的判断标准，蒸馏水对照管在0.5小时完全溶血。生理盐水和本发明实施例4-9缩宫素粉针和卡贝缩宫素粉针在3小时内均无溶血现象。轻轻振摇，生理盐水和缩宫素粉针和卡贝缩宫素粉针管底沉积的红细胞均能完全分散，表明本发明缩宫素类似物药用组合物无红细胞凝聚反应。
5、急性全身毒性试验
取健康小鼠35只，将小鼠随机分为试验组和对照组，将小鼠放入固定器内。试验组自尾静脉分别注入本发明实施例4-9制备的缩宫素类似物药用组合物供试液(每个实施例5只)，对照组注入空白对照液，注射速度为0.1ml/s，注射剂量为50ml/kg。注射完毕后，观察小鼠即时反应，并于4、24、48和72小时，观察和记录试验组和对照组动物的一般状态、毒性表现和死亡动物数。
表格7注射后动物反应观察指标
Figure PCTCN2017092717-appb-000030
按照上述方法以及表7的观察指标，在72小时观察期内，试验组动物的反应不大于对照组动物，动物无中毒反应，无动物死亡，体质量无明显变化。
综上所述，注射本发明实施例4-9制备的缩宫素类似物药用组合物具有良好的组织相容性。表明本发明制备的缩宫素类似物药用组合物安全性好，可供临床注射使用。
实施例12离体子宫动物试验
取处于动情期的雌性大鼠(实验前2日ip已烯雌酚注射液0.5ml/只，可促使其进入动情期)9只，家兔9只，脱颈椎处死后剪开腹腔，找出子宫，轻轻剥离；在子宫二角相连处下端剪断，取出子宫，置于有营养液的培养皿内。将子宫二角相连处剪开，取一角，剪取2cm，一端用标本钩钩上固定在浴槽底部，另一端用线用标本钩钩上固定在浴槽底部，另一端用线结扎与传感器相连。浴槽的营养液以能浸没子宫为宜。水浴温度为37±0.5℃，静置15min，待子宫适应后，开始实验。打开BL-420F生物机能实验系统，开始实验。用1ml注射用水分别溶解实施例1-9，并开始给药。计算子宫收缩的强度、频率和子宫收缩活力。
表格8子宫收缩的强度、频率和子宫收缩活力结果表
Figure PCTCN2017092717-appb-000031
Figure PCTCN2017092717-appb-000032
结果表明本发明的实施例4-9对大鼠、家兔离体子宫平滑肌均有明显的兴奋作用，收缩的幅度增高，频率加快，张力增加，并呈量效关系；本发明的实施例4-9能对不同的子宫产生相同的兴奋作用，对个体无效果差异。
而实施例1-3对大鼠离体子宫平滑肌有兴奋作用，但对家兔离体子宫平滑肌兴奋作用较弱，存在个体差异。

Claims (10)

  1. 一种含缩宫素类似物的药物组合物，其包含缩宫素类似物、赋形剂以及2价金属离子盐。
  2. 根据权利要求1所述的药物组合物，其中，缩宫素类似物选自缩宫素、卡贝缩宫素、那卡缩宫素、卡古缩宫素中的一种或两种以上组合。
  3. 根据权利要求1-2任一项所述的药物组合物，其中，2价金属离子盐选自钙离子盐或锌离子盐，优选为氯化钙、醋酸钙、柠檬酸钙、酒石酸钙、氯化锌、葡萄糖酸锌、葡萄糖酸钙、硫酸钙、硫酸锌、醋酸锌、柠檬酸锌中的一种或两种以上组合的溶液。
  4. 根据权利要求1-3任一项所述的药物组合物，其中，赋形剂选自甘露醇、乳糖、葡萄糖、蔗糖、氯化钠、山梨醇中的一种或两种以上组合。
  5. 根据权利要求2-4任一项所述药物组合物，其中，各组分的含量为：每5000IU-20000IU缩宫素，对应包含0.1mol-3mol的2价金属离子盐以及20g-100g赋形剂；或者每0.1g卡贝缩宫素，对应包含0.1mol-3mol的2价金属离子盐以及20g-100g赋形剂。
  6. 根据权利要求1-5任一项所述的药物组合物，其制剂选自注射用粉针。
  7. 根据权利要求1-6任一项所述药物组合物的制备方法，其包括如下步骤:
    1)配制0.1mol/L-3mol/L 2价金属离子盐溶液；
    2)加入赋形剂、缩宫素类似物并混合均匀；
    3)继续加入2价金属离子盐溶液至总体积；
    4)配制好的溶液灭菌后冻干；
    可选地，调节步骤1)中的2价金属离子盐溶液pH值至3.5-6.9。
  8. 根据权利要求7所述的制备方法，其中，步骤3)所得溶液的各组分浓度比例为：每5000IU/L-20000IU/L缩宫素，对应包含0.1mol/L-3mol/L的2价金属离子盐以及20g/L-100g/L赋形剂；
    或者每0.1g/L卡贝缩宫素，对应包含0.1mol/L-3mol/L的2价金属离子盐以及20g/L-100g/L赋形剂。
  9. 根据权利要求1-6任一项所述的药物组合物在制备用于子宫收缩或子宫止血的药物中的用途。
  10. 根据权利要求1-6任一项所述的药物组合物在制备用于提高子宫敏感性或消除子宫敏感性差异的药物中的用途。
PCT/CN2017/092717 2016-12-23 2017-07-13 一种含缩宫素类似物的药物组合物及其制备方法和用途 WO2018113272A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016112037114 2016-12-23
CN201611203711.4A CN108236716A (zh) 2016-12-23 2016-12-23 一种含缩宫素类似物的药物组合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
WO2018113272A1 true WO2018113272A1 (zh) 2018-06-28

Family

ID=62624350

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/092717 WO2018113272A1 (zh) 2016-12-23 2017-07-13 一种含缩宫素类似物的药物组合物及其制备方法和用途

Country Status (2)

Country Link
CN (1) CN108236716A (zh)
WO (1) WO2018113272A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
CN114983935A (zh) * 2022-06-15 2022-09-02 上海上药第一生化药业有限公司 一种缩宫素注射液及其制备工艺
WO2023247760A1 (en) * 2022-06-24 2023-12-28 Xellia Pharmaceuticals Aps Oxytocin formulation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111184687A (zh) * 2018-10-29 2020-05-22 厦门紫旭医药科技有限公司 一种缩宫素注射液及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102146122A (zh) * 2010-11-12 2011-08-10 深圳市健元医药科技有限公司 一种具有宫缩作用药物的生产工艺
CN103830720A (zh) * 2014-03-25 2014-06-04 深圳翰宇药业股份有限公司 一种含缩宫素的药物组合物
CN105451716A (zh) * 2013-07-18 2016-03-30 曼金德公司 热稳定性干粉药物组合物和方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102146122A (zh) * 2010-11-12 2011-08-10 深圳市健元医药科技有限公司 一种具有宫缩作用药物的生产工艺
CN105451716A (zh) * 2013-07-18 2016-03-30 曼金德公司 热稳定性干粉药物组合物和方法
CN103830720A (zh) * 2014-03-25 2014-06-04 深圳翰宇药业股份有限公司 一种含缩宫素的药物组合物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
CN114983935A (zh) * 2022-06-15 2022-09-02 上海上药第一生化药业有限公司 一种缩宫素注射液及其制备工艺
CN114983935B (zh) * 2022-06-15 2024-01-26 上海上药第一生化药业有限公司 一种缩宫素注射液及其制备工艺
WO2023247760A1 (en) * 2022-06-24 2023-12-28 Xellia Pharmaceuticals Aps Oxytocin formulation

Also Published As

Publication number Publication date
CN108236716A (zh) 2018-07-03

Similar Documents

Publication Publication Date Title
WO2018113272A1 (zh) 一种含缩宫素类似物的药物组合物及其制备方法和用途
Curlin et al. Cervical mucus: from biochemical structure to clinical implications
JPH04502017A (ja) 小ペプチド類の安定化水系調剤
RU2605288C2 (ru) Фармацевтическая композиция
US20220409671A1 (en) Composition for preventing or treating ocular diseases comprising amniotic epithelial cell derived exosomes
EA010650B1 (ru) Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек
CN101972224B (zh) 一种眼用原位凝胶
WO2015183230A9 (ru) Композиция на основе стабилизированного раствора активных веществ
CN104784193B (zh) 一种原人参二醇型三七皂苷的制药用途
CN108434166B (zh) 一种血塞通药物组合物及其制备方法、制剂与应用
US11479592B2 (en) Erythropoietin-derived peptide, preparation method and use thereof
RU2309744C1 (ru) Способ лечения послеродового эндометрита
JP7454288B2 (ja) 新規な獣用子宮注入剤の調製方法
RU2751034C1 (ru) Способ получения препарата для лечения эндометрита у коров
CN108236601B (zh) 一种稳定的含卡贝缩宫素的阴道给药的药用组合物及其制备方法
AU2008220583B2 (en) Use of VEGF in the treatment of retarded fetal growth in pregnancy
CN116889582B (zh) 一种组合物在制备治疗缺血性脑卒中药品中的应用
RU2744919C1 (ru) Средство для лечения эндометрита у коров
CN115300630B (zh) 贝母生物碱类化合物在制备预防和/或治疗脑缺血导致的疾病的药物中的应用
WO2023197210A1 (zh) 骨钙素在制备抗炎药物中的应用
CN104758304B (zh) 三七皂苷r1的医药用途
CN103520706B (zh) 口服用重组人血清白蛋白融合蛋白制剂配方、产品及用途
KR102644156B1 (ko) 피부 상처 또는 화상 치료 작용제
CN111544567B (zh) 一种阿托西班注射液药物组合物及制备方法
RU2475240C2 (ru) Способ коррекции иммунобиохимического статуса у коров в предродовом и послеродовом периодах

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17884970

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17884970

Country of ref document: EP

Kind code of ref document: A1